Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Dev Comp Immunol ; 123: 104140, 2021 10.
Article in English | MEDLINE | ID: mdl-34033840

ABSTRACT

Given the challenges posed by antibiotic resistant microbes and the high mortality rate associated with sepsis, there is an urgent need to develop novel peptide antibiotics that exhibit both antimicrobial and anti-inflammatory activities. Herein, we evaluated antimicrobial activity and anti-inflammatory activity of psacotheasin 2, one of the antimicrobial peptide candidates identified previously using an in silico analysis on the transcriptome of Psacothea hilaris. In addition to exhibiting antimicrobial activities against microorganisms without inducing hemolysis, psacotheasin 2 also decreased the nitric oxide production in lipopolysaccharide (LPS)-induced Raw264.7 cells. Moreover, ELISA and western blot analysis revealed that psacotheasin 2 reduced the expression levels of pro-inflammatory enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Further, we found that psacotheasin 2 markedly reduced the expression levels of pro-inflammatory cytokines (IL-6 and IL-1ß) by regulating mitogen-activated protein kinases (MAPKs) and nuclear factor-kB (NF-kB) signaling in LPS-induced Raw264.7 cells. We also confirmed that the binding of psacotheasin 2 to bacterial cell membranes occurs via a specific interaction with LPS. In mouse models of LPS-induced shock, psacotheasin 2 significantly enhanced the survival rate and recovered weight by attenuating pro-inflammatory cytokines. Thus, psacotheasin 2 could be a promising candidate as a peptide antiseptic agent.


Subject(s)
Antimicrobial Peptides/genetics , Sepsis/metabolism , Animals , Antimicrobial Peptides/metabolism , Antimicrobial Peptides/pharmacology , Bacteria/drug effects , Coleoptera/chemistry , Coleoptera/genetics , Coleoptera/immunology , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Immunity, Innate , Inflammation Mediators , Mice , NF-kappa B/metabolism , Nitric Oxide Synthase Type II/metabolism , Peptides/genetics , Peptides/metabolism , RAW 264.7 Cells , Sepsis/immunology , Signal Transduction
2.
J Microbiol Biotechnol ; 30(9): 1282-1289, 2020 Sep 28.
Article in English | MEDLINE | ID: mdl-32522957

ABSTRACT

Previously, we performed an in silico analysis of the Periplaneta americana transcriptome. Antimicrobial peptide candidates were selected using an in silico antimicrobial peptide prediction method. It was found that periplanetasin-5 had antimicrobial activity against yeast and grampositive and gram-negative bacteria. In the present study, we demonstrated the anti-inflammatory activities of periplanetasin-5 in mouse macrophage Raw264.7 cells. No cytotoxicity was observed at 60 µg/ml periplanetasin-5, and treatment decreased nitric oxide production in Raw264.7 cells exposed to lipopolysaccharide (LPS). In addition, quantitative RT-PCR and enzyme-linked immunosorbent assay revealed that periplanetasin-5 reduced cytokine (tumor necrosis factor-α, interleukin-6) expression levels in the Raw264.7 cells. Periplanetasin-5 controlled inflammation by inhibiting phosphorylation of MAPKs, an inflammatory signaling element, and reducing the degradation of IκB. Through LAL assay, LPS toxicity was found to decrease in a periplanetasin-5 dose-dependent manner. Collectively, these data showed that periplanetasin-5 had antiinflammatory activities, exemplified in LPS-exposed Raw264.7 cells. Thus, we have provided a potentially useful antibacterial peptide candidate with anti-inflammatory activities.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Periplaneta/metabolism , Pore Forming Cytotoxic Proteins/pharmacology , Animals , Cell Survival/drug effects , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Gene Expression Regulation , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/metabolism , Inflammation/drug therapy , Insect Proteins/pharmacology , Lipopolysaccharides/toxicity , Mice , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , RAW 264.7 Cells , Reactive Oxygen Species/metabolism , Signal Transduction
3.
J Microbiol Biotechnol ; 29(5): 687-695, 2019 May 28.
Article in English | MEDLINE | ID: mdl-30955257

ABSTRACT

In a previous work, we performed de novo RNA sequencing of Allomyrina dichotoma using next generation sequencing and identified several antimicrobial peptide candidates based on transcriptome analysis. Among them, a cationic antimicrobial peptide, allomyrinasin, was selected bioinformatically based on its physicochemical properties. Here, we assessed the antimicrobial and anti-inflammatory activities of allomyrinasin against microorganisms and mouse macrophage Raw264.7 cells. Allomyrinasin showed antimicrobial activities against various microbes and decreased the nitric oxide production of the lipopolysaccharide-induced Raw264.7 cells. Furthermore, quantitative RT-PCR and ELISA revealed that allomyrinasin reduced cytokine expression levels in the Raw264.7 cells. We also identified inducible nitric oxide synthase, cyclooxygenase-2 expression, and PGE2 production through western blot analysis and ELISA. We confirmed that allomyrinasin bound to bacterial cell membranes via a specific interaction with lipopolysaccharides. Taken together, these data indicate that allomyrinasin has antimicrobial and anti-inflammatory activities as exemplified in lipopolysaccharide-induced Raw264.7 cells. We have provided a potentially useful antimicrobial peptide candidate that has both antimicrobial and anti-inflammatory activities.


Subject(s)
Anti-Infective Agents/pharmacology , Anti-Inflammatory Agents/pharmacology , Antimicrobial Cationic Peptides/pharmacology , Coleoptera/chemistry , Animals , Anti-Infective Agents/chemistry , Anti-Inflammatory Agents/chemistry , Cell Survival/drug effects , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Lipopolysaccharides/adverse effects , Mice , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , RAW 264.7 Cells/drug effects
4.
Biochem Biophys Res Commun ; 490(3): 1004-1010, 2017 08 26.
Article in English | MEDLINE | ID: mdl-28666870

ABSTRACT

Recently, we reported that Lumbricusin, an antimicrobial peptide isolated from earthworm Lumbricus terrestris, enhanced neuronal proliferation and ameliorated motor dysfunction and dopaminergic neurodegeneration. Accumulating evidence suggests that neurodegeneration is the primary pathological feature of acute or chronic inflammation mediated by microglia, the resident macrophage of the central nervous system. Therefore, microglial activation inhibitors may be useful as therapeutic agents for neurodegenerative diseases. To determine whether Lumbricusin ameliorates neuroinflammation through inhibition of microglial activation by lipopolysaccharides (LPS), we newly synthesized 9-mer Lumbricusin analogues based on the amino acid sequence of Lumbricusin. One of these, Lumbricusin Analogue 5 (LumA5; QLICWRRFR-NH2), markedly reduced expression of enzymes (COX-2, iNOS), cytokines (IL-6, IL-1ß, TNF-α), and signal transduction factors (AKT, MAPKs, NF-κB) involved in inflammation triggered by LPS in vitro and in vivo. In addition, LumA5 inhibited the cytotoxicity of conditioned medium prepared by LPS-activated BV-2 microglia to neuronal SH-SY5Y cells and improved cell viability. These results indicate that LumA5 may be a potential therapeutic agent for the treatment of various neuroinflammatory conditions.


Subject(s)
Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Helminth Proteins/chemistry , Helminth Proteins/pharmacology , Microglia/drug effects , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Animals , Anti-Inflammatory Agents/therapeutic use , Cell Line , Cytokines/immunology , Helminth Proteins/therapeutic use , Inflammation/drug therapy , Inflammation/immunology , Inflammation/pathology , Lipopolysaccharides/immunology , Male , Mice , Mice, Inbred ICR , Microglia/immunology , Microglia/pathology , Mitogen-Activated Protein Kinases/immunology , Neuroprotective Agents/therapeutic use , Oligochaeta/chemistry , Proto-Oncogene Proteins c-akt/immunology , Signal Transduction/drug effects
5.
Int J Mol Sci ; 18(3)2017 Feb 28.
Article in English | MEDLINE | ID: mdl-28264489

ABSTRACT

Despite the increasing interest in insect-based bioactive products, the biological activities of these products are rarely studied adequately. Larvae of Tenebrio molitor, the yellow mealworm, have been eaten as a traditional food and provide many health benefits. Therefore, we hypothesized that T. molitor larvae might influence adipogenesis and obesity-related disorders. In the present study, we investigated the anti-adipogenic and antiobesity effects of T. molitor larvae in vitro and in vivo. The lipid accumulation and triglyceride content in mature adipocytes was reduced significantly (up to 90%) upon exposure to an ethanol extract of T. molitor larvae, without a reduction in cell viability. Exposure also resulted in key adipogenic and lipogenic transcription factors. Additionally, in adipogenic differentiation medium the extract induced phosphorylation of adenosine monophosphate (AMP)-activated protein kinase and mitogen-activated protein kinases. Daily oral administration of T. molitor larvae powder to obese mice fed high-fat diet attenuated body weight gain. We also found that the powder efficiently reduced hepatic steatosis as well as aspartate and alanine transaminase enzyme levels in mice fed a high-fat diet. Our results suggest that T. molitor larvae extract has an antiobesity effect when administered as a food supplement and has potential as a therapeutic agent for obesity.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Adipocytes/metabolism , Adipogenesis/drug effects , Biological Products/administration & dosage , Larva , Mitogen-Activated Protein Kinases/metabolism , Obesity/metabolism , Signal Transduction/drug effects , Tenebrio , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/drug effects , Adipogenesis/genetics , Adipose Tissue/anatomy & histology , Adipose Tissue/drug effects , Animals , Anti-Obesity Agents/administration & dosage , Body Weight/drug effects , Cell Differentiation/drug effects , Diet, High-Fat , Dietary Supplements , Disease Models, Animal , Fatty Liver/drug therapy , Fatty Liver/etiology , Fatty Liver/metabolism , Gene Expression Regulation/drug effects , Male , Mice , Mice, Obese , Obesity/drug therapy , Obesity/etiology , Phosphorylation , Transcription Factors/genetics , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL